274 related articles for article (PubMed ID: 12867068)
1. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
2. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
4. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
10. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Carcereny E; Ramirez JL; Sanchez-Ronco M; Isla D; Cobo M; Moran T; de Aguirre I; Okamoto T; Wei J; Provencio M; Lopez-Vivanco G; Camps C; Domine M; Alberola V; Sanchez JM; Massuti B; Mendez P; Taron M; Rosell R
Lung Cancer; 2010 Jun; 68(3):491-7. PubMed ID: 19733931
[TBL] [Abstract][Full Text] [Related]
11. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
[TBL] [Abstract][Full Text] [Related]
12. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
[TBL] [Abstract][Full Text] [Related]
13. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
[TBL] [Abstract][Full Text] [Related]
14. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Ren S; Zhou S; Wu F; Zhang L; Li X; Zhang J; Xu J; Lv M; Zhang J; Zhou C
Lung Cancer; 2012 Jan; 75(1):102-9. PubMed ID: 21676483
[TBL] [Abstract][Full Text] [Related]
15. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
20. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
